PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24899766-8	2014	SXB treatment induced a trend in reduction of the GDR (1.4 +- 0.1 vs. 1.1 +- 0.2 mumol/kgFFM/min/mUxL; P = 0.063) and a reduction in endogenous glucose production (0.24 +- 0.03 vs. 0.16 +- 0.03 mumol/kgFFM/min/mUxL: P = 0.028) per unit serum insulin.	Sodium Oxybate	0-3	insulin	Homo sapiens	242-249	
24899766-12	2014	While sodium oxybate tended to decrease systemic insulin sensitivity, it increased hepatic insulin sensitivity, suggesting tissue-specific effects.	Sodium Oxybate	6-20	insulin	Homo sapiens	49-56	
24899766-12	2014	While sodium oxybate tended to decrease systemic insulin sensitivity, it increased hepatic insulin sensitivity, suggesting tissue-specific effects.	Sodium Oxybate	6-20	insulin	Homo sapiens	91-98	
7642171-6	1995	In vitro experiment on isolated pancreatic islets demonstrated that STZ-induced loss of insulin response to glucose was also counteracted by incubation with GHB and NA (Peak insulin response to 16.4 mM glucose: 0.69 +/- 0.31 vs 3.03 +/- 0.67 microU/islet/min), but not by GHB or NA alone.	Sodium Oxybate	157-160	insulin	Homo sapiens	88-95	
7642171-6	1995	In vitro experiment on isolated pancreatic islets demonstrated that STZ-induced loss of insulin response to glucose was also counteracted by incubation with GHB and NA (Peak insulin response to 16.4 mM glucose: 0.69 +/- 0.31 vs 3.03 +/- 0.67 microU/islet/min), but not by GHB or NA alone.	Sodium Oxybate	272-275	insulin	Homo sapiens	88-95	
5465922-0	1970	[Effects of gamma-hydroxybutyrate on plasma levels of human growth hormone and insulin].	Sodium Oxybate	12-33	insulin	Homo sapiens	79-86